Waddah Arafat, M.D.

Harold C. Simmons Comprehensive Cancer Center

Internal Medicine - Hematology/Oncology
Prostate Cancer
Kidney Cancer

New Patient Appointment Accepting Virtual Visits or 214-645-4673

Biography

Waddah Arafat, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He serves as the Medical Director of the Clinical Cancer Informatics Program at Harold C. Simmons Comprehensive Cancer Center.

He earned his medical degree at Damascus University Faculty of Medicine and completed a residency in internal medicine at Indiana University School of Medicine. He then received advanced training through a hematology‐oncology fellowship at the University of Wisconsin School of Medicine.

Certified by the American Board of Internal Medicine, he joined the UT Southwestern faculty in 2018.

Dr. Arafat is a member of several professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research. He served on the Chemotherapy Review Council at the University of Wisconsin Carbone Cancer Center.

His research focuses on novel therapeutic strategies and the use of novel biomarkers to improve clinical outcomes for patients with genitourinary malignancies. He has performed both basic and clinical research and published several academic articles.

In 2017, Dr. Arafat earned the Wisconsin Association of Hematology and Oncology Fellow Award.

Education & Training

Fellowship - University of Wisconsin Health Sciences Center (2015-2018), Hematology Oncology
Residency - Indiana University School of Medicine (2010-2013), Internal Medicine
Residency - Alshami Hospital, Syria (2009-2010), Internal Medicine
Medical School - Damascus University School of Medicine, Syria (2002-2009)

Honors & Awards

Texas Monthly Super Doctors, Rising Star 2020
Fellow Award 2017, Wisconsin Association of Hematology and Oncology

Books & Publications

Publications
- Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.
  Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R, Advances in radiation oncology 2021 Sep-Oct 6 5 100692
- Disparities in Pre-Orchiectomy Sperm Cryopreservation Among Testicular Cancer Patients at a Public Safety Net Hospital and a Private Tertiary Care Center.
  Patel A, Howard JM, Chertack N, Badia RR, Margulis V, Woldu SL, Courtney K, Bowman IA, Arafat W, Meng X, Bakare T, Bagrodia A, Urology 2021 Jul
- Oncologist Perspectives on Telemedicine for Patients With Cancer: A National Comprehensive Cancer Network Survey.
  Tevaarwerk AJ, Chandereng T, Osterman T, Arafat W, Smerage J, Polubriaginof FCG, Heinrichs T, Sugalski J, Martin DB, JCO oncology practice 2021 Jul OP2100195
- Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
  Bade RM, Schehr JL, Emamekhoo H, Gibbs BK, Rodems TS, Mannino MC, Desotelle JA, Heninger E, Stahlfeld CN, Sperger JM, Singh A, Wolfe SK, Niles DJ, Arafat W, Steinharter JA, Jason Abel E, Beebe DJ, Wei XX, McKay RR, Choueri TK, Lang JM, Molecular oncology 2021 Feb
- Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.
  Hannan, R, Christensen, M, Robles,L, Christie, A, Garant,A, Desai, NB, Hammers, HJ, Arafat, W, Bowman, IA, Cole, S, Courtney, KD, Woldu, SL, Bagrodia, A, Margulis, V, Cadeddu, JA, Choy, H, Sher, D, Brugarolas J, Journal of Clinical Oncology 2021 39(6_suppl) p. 311-311.
- Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer.
  Meng X, Ahmed M, Courtney KD, Arafat W, Ibrahim I, Margulis V, Nichols C, Bagrodia A, Frontiers in oncology 2021 11 724682
- Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital.
  Chertack N, Ghandour RA, Singla N, Freifeld Y, Hutchinson RC, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Sagalowsky AI, Margulis V, Lotan Y, Woldu SL, Bagrodia A, Cancer 2020 10 126 19 4362-4370
- Prospective Safety and Feasibility trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)
  S.All, A.Diaz de Leon, O.Mohamad, H.Choy, H.Hammers, A.Sanjeevaiah, W.Arafat, K.Courtney, R.D.Timmermanm J.Brugarolas, R.Hannan International Journal of Radiation Oncology, Biology, Physics 2020 108 3, suppl_1 e896-e897
- Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial.
  Arafat, W, Desotelle, J, Rodems, T, McKay, RR, Abel, J, Choueiri, TK, Lang, JM Journal of Clinical Oncology 2017 35, no. 15_suppl p. 4579-4579.
- Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.
  Arafat, W, Stahlfeld, C, Sperger, JM, Heninger, E, Gopalakrishnan, D, Barata, PC, Lamenza, M, Devonshire, S, Hoxha, N, Profusek, P, Rini, Bi, Ornstein, MC, Garcia, JA, Kyriakopoulos, C, Lang, JM, Grivas, P Journal of Clinical Oncology 2017 35, no. 15_suppl
- Inferior Vena Cava Filter - Appropriate Use and Retrieval
  Shah, R, Turk, A, Rahim, B, Arafat, W, Nazeef, M, Mattison, RJ Blood 2016 128(22) p. 5912-5912.
- Very late relapse of germ cell tumor as a teratoma: a case report and review of the literature.
  Arafat W, Albany C, Ulbright TM, Foster R, Einhorn LH Journal of surgical case reports 2014 Jun 2014 6

Clinical Focus

Prostate Cancer
Kidney Cancer
Bladder Cancer
Testicular Cancer